Preliminary results from Nektar Therapeutics' NKTR-102 Phase 2 study in platinum-resi

[News]

Nektar Therapeutics today announced preliminary results from the first stage of a two-stage Phase 2 clinical study evaluating NKTR-102 in women with platinum-resistant ovarian cancer. In the first stage of the study, 39 patients enrolled with platinum-resistant disease were evaluable for the primary endpoint of overall response rate using Gynecologic Cancer InterGroup (GCIG) criteria, i.e., a combination of response by tumor imaging

More... (http://www.news-medical.net/news/20100112/Preliminary-results-from-Nektar-Therapeutics-NKTR-102-Phase-2-study-in-platinum-resistant-ovarian-cancer.aspx)